{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:43:20Z","timestamp":1783381400266,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05963-8","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:25:55Z","timestamp":1756988755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["From diagnostic uncertainty to targeted therapy: a case-based review of VEXAS syndrome"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-6836","authenticated-orcid":false,"given":"Gunjan","family":"Rana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3996-6799","authenticated-orcid":false,"given":"Mansi","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1483-2241","authenticated-orcid":false,"given":"Arash","family":"Mollaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"5963_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.129","volume":"8","author":"AM Aalbers","year":"2024","unstructured":"Aalbers AM, van Daele PLA, Dalm VASH, Valk PJM, Raaijmakers MHGP (2024) Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome. Hemasphere 8:e129","journal-title":"Hemasphere"},{"key":"5963_CR2","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1038\/s41433-024-03014-3","volume":"38","author":"M Abumanhal","year":"2024","unstructured":"Abumanhal M, Leibovitch I, Zisapel M, Eviatar T, Edel Y, Ben Cnaan R (2024) Ocular and orbital manifestations in VEXAS syndrome. Eye 38:1748\u20131754","journal-title":"Eye"},{"key":"5963_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00403-022-02340-4","volume":"315","author":"V Afsahi","year":"2023","unstructured":"Afsahi V, Christensen RE, Alam M (2023) VEXAS syndrome in dermatology. Arch Dermatol Res 315:161\u2013164","journal-title":"Arch Dermatol Res"},{"key":"5963_CR4","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383:2628\u20132638","journal-title":"N Engl J Med"},{"key":"5963_CR5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jama.2022.24836","volume":"329","author":"DB Beck","year":"2023","unstructured":"Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y et al (2023) Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population. JAMA 329:318\u2013324","journal-title":"JAMA"},{"key":"5963_CR6","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e225","volume":"39","author":"IC Benlidayi","year":"2024","unstructured":"Benlidayi IC, Gupta L (2024) CAse-BAsed REview sTandards (CABARET): considerations for authors, reviewers, and editors. J Korean Med Sci 39:e225","journal-title":"J Korean Med Sci"},{"key":"5963_CR7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00277-024-06037-8","volume":"104","author":"B C\u00e1ceres-Nazario","year":"2025","unstructured":"C\u00e1ceres-Nazario B, Rivenbark J, Saha MK, Mathews S, Rubinstein SM (2025) Novel use of Siltuximab in a patient with VEXAS syndrome. Ann Hematol 104:1259\u20131267","journal-title":"Ann Hematol"},{"key":"5963_CR8","first-page":"1449","volume":"40","author":"H Ciferska","year":"2022","unstructured":"Ciferska H, Gregov\u00e1 M, Klein M, \u0160enolt L, Soukupov\u00e1 Maaloufov\u00e1 J, Pavelka K et al (2022) VEXAS syndrome: a report of three cases. Clin Exp Rheumatol 40:1449","journal-title":"Clin Exp Rheumatol"},{"key":"5963_CR9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","volume":"6","author":"A Diarra","year":"2022","unstructured":"Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L et al (2022) Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv 6:998\u20131003","journal-title":"Blood Adv"},{"key":"5963_CR10","doi-asserted-by":"publisher","first-page":"1354130","DOI":"10.3389\/fimmu.2024.1354130","volume":"15","author":"E Diral","year":"2024","unstructured":"Diral E, Campochiaro C, Tomelleri A, Bergonzi GM, Pizzano U, Ponzoni M et al (2024) Case report: cytopenias in VEXAS syndrome\u2014a WHO 2022 based approach in a single-center cohort. Front Immunol 15:1354130","journal-title":"Front Immunol"},{"key":"5963_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae123","author":"R Echerbault","year":"2024","unstructured":"Echerbault R, Bourguiba R, Georgin-Lavialle S, Lavigne C, Ravaiau C, Lacombe V (2024) Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keae123","journal-title":"Rheumatology"},{"key":"5963_CR12","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/art.41743","volume":"73","author":"MA Ferrada","year":"2021","unstructured":"Ferrada MA, Sikora KA, Luo Y, Wells KV, Patel B, Groarke EM et al (2021) Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol 73:1886\u20131895","journal-title":"Arthritis Rheumatol"},{"key":"5963_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ajh.27169","volume":"99","author":"C Gurnari","year":"2024","unstructured":"Gurnari C, Pascale MR, Vitale A, Diral E, Tomelleri A, Galossi E et al (2024) Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort. Am J Hematol 99:254\u2013262","journal-title":"Am J Hematol"},{"key":"5963_CR14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/imj.15742","volume":"52","author":"S Islam","year":"2022","unstructured":"Islam S, Cullen T, Sumpton D, Damodaran A, Heath D, Bosco A et al (2022) VEXAS syndrome: lessons learnt from an early Australian case series. Intern Med J 52:658\u2013662","journal-title":"Intern Med J"},{"key":"5963_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-44811-4","volume":"15","author":"O Kosmider","year":"2024","unstructured":"Kosmider O, Poss\u00e9m\u00e9 C, Templ\u00e9 M, Corneau A, Carbone F, Duroyon E et al (2024) VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. Nat Commun 15:1\u201317","journal-title":"Nat Commun"},{"key":"5963_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/RHU.0000000000001905","volume":"29","author":"MJ Koster","year":"2023","unstructured":"Koster MJ, Samec MJ, Warrington KJ (2023) VEXAS syndrome\u2014a review of pathophysiology, presentation, and prognosis. JCR J Clin Rheumatol 29:298","journal-title":"JCR J Clin Rheumatol"},{"key":"5963_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00296-023-05513-0","volume":"44","author":"K Kouranloo","year":"2024","unstructured":"Kouranloo K, Dey M, Almutawa J, Myall N, Nune A (2024) Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review. Rheumatol Int 44:1219\u20131232","journal-title":"Rheumatol Int"},{"key":"5963_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.5114\/reum\/163090","volume":"61","author":"EJ Kucharz","year":"2023","unstructured":"Kucharz EJ (2023) VEXAS syndrome: a newly discovered systemic rheumatic disorder. Reumatologia 61:123\u2013129","journal-title":"Reumatologia"},{"key":"5963_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901063","volume":"13","author":"Y Kunishita","year":"2022","unstructured":"Kunishita Y, Kirino Y, Tsuchida N, Maeda A, Sato Y, Takase-Minegishi K et al (2022) Case report: Tocilizumab treatment for VEXAS syndrome with relapsing polychondritis: a single-center, 1-year longitudinal observational study in Japan. Front Immunol 13:901063","journal-title":"Front Immunol"},{"issue":"4","key":"5963_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s13671-024-00450-y","volume":"13","author":"M Kwan","year":"2024","unstructured":"Kwan M, Yang CS, Nguyen CV (2024) VEXAS syndrome: a review for the inpatient dermatologist. Curr Dermatol Rep 13(4):324\u2013329","journal-title":"Curr Dermatol Rep"},{"key":"5963_CR21","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3026(23)00375-7","volume":"11","author":"V Lacombe","year":"2024","unstructured":"Lacombe V, Hadjadj J, Georgin-Lavialle S, Lavigne C, Genevi\u00e8ve F, Kosmider O (2024) Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond. Lancet Haematol 11:e160\u2013e167","journal-title":"Lancet Haematol"},{"key":"5963_CR22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bjh.17679","volume":"195","author":"V Lacombe","year":"2021","unstructured":"Lacombe V, Prevost M, Bouvier A, Th\u00e9pot S, Chabrun F, Kosmider O et al (2021) Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold. Br J Haematol 195:286\u2013289","journal-title":"Br J Haematol"},{"key":"5963_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/bloodadvances.2021005243","volume":"6","author":"P Li","year":"2022","unstructured":"Li P, Venkatachalam S, Ospina Cordona D, Wilson L, Kovacsovics T, Moser KA et al (2022) A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm. Blood Adv 6:405\u2013409","journal-title":"Blood Adv"},{"key":"5963_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaci.2021.05.014","volume":"149","author":"CI van der Made","year":"2022","unstructured":"van der Made CI, Potjewijd J, Hoogstins A, Willems HPJ, Kwakernaak AJ, de Sevaux RGL et al (2022) Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of patients with VEXAS. J Allergy Clin Immunol 149:432\u20139.e4","journal-title":"J Allergy Clin Immunol"},{"key":"5963_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/art.41992","volume":"74","author":"F Muratore","year":"2022","unstructured":"Muratore F, Marvisi C, Castrignan\u00f2 P, Nicoli D, Farnetti E, Bonanno O et al (2022) VEXAS syndrome: a case series from a single-center cohort of Italian patients with vasculitis. Arthritis Rheumatol 74:665\u2013670","journal-title":"Arthritis Rheumatol"},{"key":"5963_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03799-9","author":"H Nakajima","year":"2024","unstructured":"Nakajima H, Kunimoto H (2024) VEXAS syndrome. Int J Hematol. https:\/\/doi.org\/10.1007\/s12185-024-03799-9","journal-title":"Int J Hematol"},{"key":"5963_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-251089","author":"K Neupane","year":"2022","unstructured":"Neupane K, Jayarangaiah A, Zhang Y, Kumar A (2022) VEXAS syndrome with progression of MDS to MDS\/MPN overlap syndrome. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2022-251089","journal-title":"BMJ Case Rep"},{"key":"5963_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/ajd.13932","volume":"63","author":"JK Nguyen","year":"2022","unstructured":"Nguyen JK, Routledge D, van Der Weyden C, Blombery P, Angel CM, Johnson D et al (2022) VEXAS syndrome: a dermatological perspective. Australas J Dermatol 63:488\u2013492","journal-title":"Australas J Dermatol"},{"key":"5963_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.seminhematol.2021.10.005","volume":"58","author":"BA Patel","year":"2021","unstructured":"Patel BA, Ferrada MA, Grayson PC, Beck DB (2021) VEXAS syndrome: an inflammatory and hematologic disease. Semin Hematol 58:201\u2013203","journal-title":"Semin Hematol"},{"key":"5963_CR30","doi-asserted-by":"publisher","first-page":"1403808","DOI":"10.3389\/fimmu.2024.1403808","volume":"15","author":"R da Pereira Costa","year":"2024","unstructured":"da Pereira Costa R, Sapinho G, Bandeira M, Infante J, Marques T, Mimoso Santos C et al (2024) Case report: VEXAS syndrome: an atypical indolent presentation as sacroiliitis with molecular response to azacitidine. Front Immunol. 15:1403808","journal-title":"Front Immunol."},{"key":"5963_CR31","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood.2020010286","volume":"137","author":"JA Poulter","year":"2021","unstructured":"Poulter JA, Collins JC, Cargo C, De Tute RM, Evans P, Ospina Cardona D et al (2021) Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood 137:3676\u20133681","journal-title":"Blood"},{"key":"5963_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15050","volume":"33","author":"AJ Saad","year":"2024","unstructured":"Saad AJ, Patil MK, Cruz N, Lam CS, O\u2019Brien C, Nambudiri VE (2024) VEXAS syndrome: a review of cutaneous findings and treatments in an emerging autoinflammatory disease. Exp Dermatol 33:e15050","journal-title":"Exp Dermatol"},{"key":"5963_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678927","volume":"12","author":"F Staels","year":"2021","unstructured":"Staels F, Betrains A, Woei-A-Jin FJSH, Boeckx N, Beckers M, Bervoets A et al (2021) Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome. Front Immunol 12:678927","journal-title":"Front Immunol"},{"key":"5963_CR34","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1093\/rheumatology\/keab524","volume":"60","author":"M Templ\u00e9","year":"2021","unstructured":"Templ\u00e9 M, Duroyon E, Croizier C, Rossignol J, Huet T, Friedrich C et al (2021) Atypical splice-site mutations causing VEXAS syndrome. Rheumatology (Oxford) 60:e435\u2013e437","journal-title":"Rheumatology (Oxford)"},{"key":"5963_CR35","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11739-023-03193-z","volume":"18","author":"A Vitale","year":"2023","unstructured":"Vitale A, Caggiano V, Bimonte A, Caroni F, Tosi GM, Fabbiani A et al (2023) VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases. Intern Emerg Med 18:711\u2013722","journal-title":"Intern Emerg Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05963-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05963-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05963-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:14:29Z","timestamp":1760523269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05963-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["5963"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05963-8","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from both patients for publication of their clinical information and accompanying images. Identifying details have been omitted to ensure confidentiality. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"217"}}